This study is looking for patients with Type 2 Diabetes who are currently using Lantus or Basaglar. Patients will either remain on their insulin or will have a once-weekly study injection added to reduce the amount of insulin taken.
The once-weekly study injection is already approved on the market.
Study participants may receive study-related care and study medication or an approved medication at no charge. You may also receive compensation for travel expenses.
Participant Eligibility Criteria ( To take part in the study )